Abstract
Signals mediated by CXCL12 (SDF1) and its receptor CXCR4 are centrally involved in cancer progression, both directly by activating cancer cells and indirectly by inducing angiogenesis plus recruiting T regulatory and plasmacytoid dendritic immune cells. Here, we show that in ascites isolated from ovarian cancer patients, both CXCL12 and CXCR4 are controlled by the tumor-associated inflammatory mediator prostaglandin E(2) (PGE(2)), which attracts myeloid-derived suppressor cells (MDSC) into the ascites microenvironment. In this setting, PGE(2) was essential both for expression of functional CXCR4 in cancer-associated MDSCs and for production of its ligand CXCL12. Frequencies of CD11b(+)CD14(+)CD33(+)CXCR4(+) MDSCs closely correlated with CXCL12 and PGE(2) levels in patient ascites. MDSCs migrated toward ovarian cancer ascites in a CXCR4-dependent manner that required COX2 activity and autocrine PGE(2) production. Inhibition of COX2 or the PGE(2) receptors EP2/EP4 in MDSCs suppressed expression of CXCR4 and MDSC responsiveness to CXCL12 or ovarian cancer ascites. Similarly, COX2 inhibition also blocked CXCL12 production in the ovarian cancer environment and its ability to attract MDSCs. Together, our findings elucidate a central role for PGE(2) in MDSC accumulation triggered by the CXCL12-CXCR4 pathway, providing a powerful rationale to target PGE(2) signaling in ovarian cancer therapy.
MeSH Terms
Biphenyl Compounds/pharmacology
CD11b Antigen/genetics,metabolism
Celecoxib
Cell Movement
Cells, Cultured
Chemokine CXCL12/genetics,metabolism
Cyclooxygenase 2/genetics,metabolism
Cyclooxygenase 2 Inhibitors/pharmacology
Dinoprostone/metabolism
Female
Flow Cytometry
Gene Expression Regulation, Neoplastic
Humans
Monocytes/drug effects,metabolism,pathology
Myeloid Cells/drug effects,metabolism,pathology
Ovarian Neoplasms/genetics,metabolism,pathology
Prostaglandin Antagonists/pharmacology
Pyrazoles/pharmacology
Receptors, CXCR4/genetics,metabolism
Receptors, Prostaglandin E, EP2 Subtype/antagonists & inhibitors,metabolism
Receptors, Prostaglandin E, EP4 Subtype/antagonists & inhibitors
Sulfonamides/pharmacology
Tumor Cells, Cultured
Tumor Microenvironment/drug effects
Xanthones/pharmacology
Chemicals
Biphenyl Compounds
CD11b Antigen
CXCR4 protein, human
Chemokine CXCL12
Cyclooxygenase 2 Inhibitors
ITGAM protein, human
PTGER2 protein, human
Prostaglandin Antagonists
Pyrazoles
Receptors, CXCR4
Receptors, Prostaglandin E, EP2 Subtype
Receptors, Prostaglandin E, EP4 Subtype
Sulfonamides
Xanthones
6-isopropoxy-9-oxoxanthene-2-carboxylic acid
AH 23848
Cyclooxygenase 2
PTGS2 protein, human
Celecoxib
Dinoprostone
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Obermajer Natasa
Department of Surgery, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Muthuswamy Ravikumar
Odunsi Kunle
Edwards Robert P
Kalinski Pawel
Conflict of Interest
of Potential Conflicts of Interest No potential conflicts of interest were disclosed.
References (39)
39 references, click to expand
-
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Cancer Res. 2007 May 1;67(9):4507-13
PMID: 17483367
-
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.
J Immunol. 2000 Jul 15;165(2):779-85
PMID: 10878351
-
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
J Immunol. 2008 Jul 1;181(1):346-53
PMID: 18566400
-
Prostaglandins and cancer.
Gut. 2006 Jan;55(1):115-22
PMID: 16118353
-
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol. 2009 Mar;9(3):162-74
PMID: 19197294
-
Immunosuppressive networks in the tumour environment and their therapeutic relevance.
Nat Rev Cancer. 2005 Apr;5(4):263-74
PMID: 15776005
-
Mechanisms and functional significance of tumour-induced dendritic-cell defects.
Nat Rev Immunol. 2004 Dec;4(12):941-52
PMID: 15573129
-
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine.
Cancer Res. 2008 Jul 15;68(14):5965-71
PMID: 18632652
-
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
Blood. 1998 Dec 1;92(11):4150-66
PMID: 9834220
-
Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 2007;25:267-96
PMID: 17134371
-
Regulatory T cells, tumour immunity and immunotherapy.
Nat Rev Immunol. 2006 Apr;6(4):295-307
PMID: 16557261
-
Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses.
Microcirculation. 2003 Jun;10(3-4):359-70
PMID: 12851652
-
COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
Am J Pathol. 2010 Mar;176(3):1469-83
PMID: 20110411
-
Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer.
Int J Cancer. 2012 Mar 1;130(5):1109-19
PMID: 21480223
-
Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.
Cancer Res. 2008 Jul 15;68(14):5972-8
PMID: 18632653
-
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Cancer Res. 2002 Oct 15;62(20):5930-8
PMID: 12384559
-
Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Int J Cancer. 2008 Jan 1;122(1):91-9
PMID: 17893878
-
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.
Nat Med. 2001 Dec;7(12):1339-46
PMID: 11726975
-
Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.
J Immunother. 2010 Feb-Mar;33(2):126-35
PMID: 20145550
-
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
Cell. 2005 May 6;121(3):335-48
PMID: 15882617
-
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages.
Nat Immunol. 2000 Dec;1(6):510-4
PMID: 11101873
-
Tumor escape mechanism governed by myeloid-derived suppressor cells.
Cancer Res. 2008 Apr 15;68(8):2561-3
PMID: 18413722
-
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.
Blood. 2010 Sep 2;116(9):1454-9
PMID: 20498301
-
Cancer and the chemokine network.
Nat Rev Cancer. 2004 Jul;4(7):540-50
PMID: 15229479
-
Immature myeloid cells and cancer-associated immune suppression.
Cancer Immunol Immunother. 2002 Aug;51(6):293-8
PMID: 12111117
-
Decreased antigen presentation by dendritic cells in patients with breast cancer.
Clin Cancer Res. 1997 Mar;3(3):483-90
PMID: 9815709
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Nat Med. 2004 Sep;10(9):942-9
PMID: 15322536
-
Tumor-induced immune dysfunctions caused by myeloid suppressor cells.
J Immunother. 2001 Nov-Dec;24(6):431-46
PMID: 11759067
-
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.
Clin Cancer Res. 2003 Mar;9(3):961-8
PMID: 12631593
-
Cyclooxygenases in cancer: progress and perspective.
Cancer Lett. 2004 Nov 8;215(1):1-20
PMID: 15374627
-
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
Cancer Res. 2005 Jan 15;65(2):465-72
PMID: 15695388
-
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.
Cancer Res. 2004 Mar 1;64(5):1853-60
PMID: 14996749
-
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
Cancer Res. 2000 Jul 15;60(14):3696-700
PMID: 10919635
-
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 2001 Mar 1;410(6824):50-6
PMID: 11242036
-
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
Semin Cancer Biol. 2006 Feb;16(1):53-65
PMID: 16168663
-
The terminology issue for myeloid-derived suppressor cells.
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
PMID: 17210725
-
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.
Blood. 1998 Dec 15;92(12):4778-91
PMID: 9845545
-
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.
Cancer Res. 2004 Nov 15;64(22):8451-5
PMID: 15548717
-
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells.
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2736-41
PMID: 12598658